Doc Gumshoe explains CRISPR, CAR-T and more...
23 Comments Read MoreArticles
A Look at the Promise of Gene Editing
“‘Cut & Paste’ Disease From Your Body” — what’s this “Living Software” Business from Dylan Jovine?
Looking Backward – And a Peek in the Other Direction
Doc Gumshoe looks at the state of cancer treatment... and some of the interesting drug approvals from 2018
14 Comments Read MoreAbiding Ambiguity: Achaogen and Arrowhead
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
151 Comments Read More 
Cancer Care: Current Directions
The Long Case for Receptos
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
885 Comments Read More Cancer Care: Where Are We and Where Are We Headed?
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
36 Comments Read MoreThe 2015 Stock Gumshoe Biotechnology Awards Show!
Biotech Dim Sum: ARTH, CLDN, ESPR, BLRX, GILD and a New Baby Biotech for 2015
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
544 Comments Read More Dawn of the Planet of the TLOGlodytes!
Special Update on Cellceutix
[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]
308 Comments Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
What a lovely experience; customer service is excellent as the previous reviewers stated. I needed to cancel my subscrip...
After going thoroughly over their trading methodology, it is both sound and makes sense. One aspect of their trading ...
I am from Kenya, in africa.i have read about the “No. 1 Stock in 2019” — $3 “Single Stock Retirement Plan” tra...
Ok Thanks Julie; I thought you had to pair the trade as separate transactions yourself and that's why I mentioned how t...
Took the words right out of my mouth. Kind of wished I had got some of SPOT when it ticked under 125 a couple of weeks ...
ARK Genomic Revolution Multi-Sector ETF—ARKG This one has EDIT, CELG, NTLA, CRSP......
EDIT and CELG are Motley Fool favorites also. Lost money on CELG....
Motley Fool has been touting BLUE for a while. They've also been touting Celgene (CELG) which hasn't done a whole lot si...
$CELG - What caused Celgene's latest snafu?; Judge shreds Shkreli (YUCK) defense, leaves him exposed to hard timeT...
$SRNE LONGJuno acquisition bodes well for Sorrento, says H.C. Wainwright H.C. Wainwright analyst Raghuram Selvara...
$BIOC long - Form SC 13D/A / Amended General Statement of Beneficial Ownership http://ir.biocept.com/secfiling.cfm?fil...
Recent deal maker with Celgene (CELG) Jounce to IPO.http://marketexclusive.com/worth-following-celgene-corporation-n...
Given its now large size and similar reliance on a single category of drugs, do you see Celgene ($CELG) headed down the...
Celgene (CELG) on the hunt ?http://endpts.com/analyst-celgene-looks-ready-to-pop-a-new-multiple-myeloma-deal/?utm_me...
Celgene (CELG) plots speedy FDA filing on blood cancer drug with partner Agios (AGIO).http://www.xconomy.com/boston/...
Interesting story on Celgene (CELG) and their drug Thalomid.http://www.bloomberg.com/news/articles/2016-08-22/from-n...
SRNE news today.Hires former CMO of Celgene (CELG) http://finance.yahoo.com/news/dr-jerome-zeldis-m-d-130000130.htm...
$CELG ncp - Analyst Brian Abrahams from Jefferies reiterated a Buy rating on Celgene ($CELG) 4.6 stars Analyst Averag...
#CELG via Tipranks.com - Analyst Eric Schmidt from Cowen & Co. reiterated a Buy rating on Celgene (CELG), with a $15...
Celgene (CELG) signs big deal with 2.56 billion dollar deal with Jounce Therapeutics. This is quite a big deal. http://...
$CELG long- tipranks.com Analyst Ying Huang from Merrill Lynch reiterated a Buy rating on Celgene (CELG), with a $125 p...
Analysts Chime In on Depomed Inc (DEPO) and Celgene Corporation (CELG) Following Starboard’s Activism Announcement and...
An update regarding investigational drug RPC-4046.Recall our prior column on Receptos: readers who went long this st...
Which drugs will drive valuations for Celgene (CELG) in 2016.http://marketrealist.com/2016/03/celgene-valuation-comp...
Daniels who is currently Chairman of research of Celgene (CELG) brings a lot of clout to Zafgen, excellent add.Cheer...
The best Celgene (CELG) headlines of 2015.http://www.fool.com/investing/general/2016/01/01/the-best-celgene-corporat...
Cramer 4 Biotech's to buy for 2016 include Gilead (GILD) and Celgene (CELG).http://www.cnbc.com/2015/12/23/cramer-bi...
CELGENE (CELG) Research.A Holiday Gift; Settling Revlimid Patent Overhang - Reiterate BUY and $163 PTInvestme...
Celgene (CELG) Blood cancer drug could be a big winner. http://blogs.barrons.com/stockstowatchtoday/2015/12/07/celgene-...
Baron's top 10 for 2016 includes Celgene (CELG). http://finance.yahoo.com/news/barrons-recap-top-picks-2016-231304846.h...
Positive article on Celgene (CELG), what Doc Kss has been telling us for a long time. CELG possibly one of the best run ...
JP Morgan goes to overweight on Celgene (CELG). smaller Larger By Ben LevisohnIn upgrading Celgene (CELG) to...
Interesting Baron's article. Gilead Science, How bad can it get?Email Print smaller Larger By Ben Levisohn ...
Celgene (CELG) one of Jefferies top picks. http://247wallst.com/healthcare-business/2015/09/11/jefferies-starts-coverag...
Adam Feuerstein's column on Monday's volatility (pretty sure he could be describing most Gummies here as well):"I wi...
Nice article on Celgene (CELG). http://education.investors.com/ibd-stock-analysis/082115-767715-biotech-celgene-juno-th...
Nice summary of Celgene (CELG). http://seekingalpha.com/article/3335345-celgene-new-deals-creating-more-compelling-inve...
Link did not work on Celgene (CELG) licensing deals and valuation on above.Try this one. Normally do not like Seeking Al...
Interesting perspective on Celgene (CELG) latest licensing deals and valuation. I tend to agree with this article for th...
Thoughts on Celgene (CELG) on boosting share repurchase plan. http://www.investopedia.com/stock-analysis/062215/celgene...
Celgene (CELG) announces 4 billion dollar stock buy back. http://finance.yahoo.com/news/celgene-announces-additional-4-...
Interesting on Celgene (CELG) and CAR-T take. http://www.investopedia.com/stock-analysis/060815/celgene-takes-step-back...
Glenn and Om had recently brought up Momenta as a play on the biosimilars space.What are biosimilars?They can be...
From SA: Luspatercept Fast Track'd for beta thalassemiaThe FDA designates luspatercept for Fast Track review for th...
What Doc Kss has been telling us about Celgene (CELG) all along. http://www.cnbc.com/id/102676161?__source=yahoo%7Cfina...
Great to have some conservative Biotech in your lineup like Celgene (CELG).Martin Zweig - Conservative Growth Invest...
Kris, GBIM looks very interesting with Gileads (GILD) backing in HBV and also a partnership with Celgene (CELG) that loo...
Celgene (CELG) and Activus (ACT) set to join S&P 100. http://finance.yahoo.com/news/celgene-kinder-morgan-actavis-set-2...
Celgene (CELG) getting some action. http://www.cnbc.com/id/102492475?__source=yahoo%7cfinance%7cheadline%7cheadline%7cs...
Celgene (CELG) news. http://www.investopedia.com/articles/investing/022615/celgenes-approval-means-sales-could-surge.as...
More good new from Celgene (CELG) this morning. Long CELG. http://finance.yahoo.com/news/celgene-announces-positive-rec...
Celgene (CELG) is a machine.They just keep spitting out good news on their drugs. http://www.rttnews.com/2445565/celgen...
Wow, Celgene (CELG) expects to triple profits by 2020. http://247wallst.com/healthcare-business/2015/01/12/celgene-expe...
Nice article on Celgene (CELG) today at Barrons.As Doc has said this company is simply loaded across the board with gre...
An extemporaneous shout-out to readers here about a topic that comes up now and again: Celgene $CELG. I have owned share...
Thanks, doc. I'll definitely try to make time when I can. I'll be traveling a lot more, though, and it's sometimes har...
Celgene $CELG CEO has made major transactions in his company's shares per new SEC filing:http://ir.celgene.com/secfi...
Celgene (CELG) is planning a 2:1 stock split this summer. A great company with room to run,...
Morgan Stanley has 44 stocks on takeover target radar, including 3 biopharma - Celgene (CELG), Regeneron (REGN) and Ale...